SAGHMOS THERAPEUTICS
SAGHMOS THERAPEUTICS
Industry:
Biotechnology Medical Medical Device Pharmaceutical
Address:
Greenwich, Connecticut, United States
Country:
United States
Status:
Active
Contact:
914-522-3885
Similar Organizations
Omnitura Therapeutics
Omnitura Therapeutics is a biopharmaceutical company .
More informations about "Saghmos Therapeutics"
Saghmos Therapeutics Company Profile 2024: Valuation, Funding ...
Saghmos Therapeutics General Information Description. Operator of a privately held biopharmaceutical company intended for life-threatening cardiovascular and renal diseases …See details»
Saghmos Therapeutics - LinkedIn
Saghmos Therapeutics is a privately held biopharmaceuticals company with a Phase 3-ready cardiorenal metabolic modulator ST-62516 (trimetazidine). Saghmos’ IND for ST-62516 was …See details»
Saghmos Therapeutics - VentureRadar
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is …See details»
Saghmos Therapeutics Announces Collaboration with Duke Clinical ...
Apr 17, 2024 DCRI is the world’s largest academic clinical research organization and a pioneer in cardiovascular clinical research, combining clinical and academic leadership with …See details»
Saghmos Therapeutics - Overview, News & Similar companies
Mar 12, 2024 Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study GREENWICH, Conn.- …See details»
Saghmos Therapeutics, Inc. - BIO CEO & Investor Conference | BIO
Feb 6, 2023 Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to develop innovative therapies for life-threatening cardiovascular and renal …See details»
Saghmos Therapeutics, Inc. Company Profile | Greenwich, CT ...
Find company research, competitor information, contact details & financial data for Saghmos Therapeutics, Inc. of Greenwich, CT. Get the latest business insights from Dun & Bradstreet.See details»
Saghmos Therapeutics - Contacts, Employees, Board Members
Saghmos Therapeutics is a privately held biopharmaceuticals company with a Phase 3-ready cardiorenal metabolic modulator. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Saghmos Therapeutics - BioCT
15 East Putnam Avenue, #430 Greenwich, CT 06830. Phone: 914-522-3885 Fax: 914-206-3548. Email: [email protected] General Information: Saghmos Therapeutics is a privately held …See details»
Saghmos Therapeutics - Products, Competitors, Financials, …
About Saghmos Therapeutics. Saghmos Therapeutics is a company focused on biotechnology and the development of therapeutic solutions. The company is engaged in medical research to …See details»
Anna Kazanchyan, MD - BIO CEO & Investor Conference | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Anna Kazanchyan, M.D. is …See details»
Full List of Pharmaceutical Companies in Connecticut, US (2024)
Jul 26, 2023 BioCT is the Connecticut state affiliate to the Biotechnology Innovation Organization (BIO). It has biotech, medtech, pharma companies, and clinical research …See details»
Saghmos Therapeutics Announces Presentation at the Citi Global ...
Dec 3, 2024 Saghmos Therapeutics, Inc. Anna Kazanchyan, MD Founder and CEO +1 914 522 3885 [email protected] or LaVoie Health Science Paul Sagan VP, Investor Relations and …See details»
Saghmos Therapeutics Announces Presentation at UBS 2024 …
Sep 17, 2024 Saghmos Therapeutics, Inc. Anna Kazanchyan, MD Founder and CEO +1 914 522 3885 [email protected] or LaVoie Health Science Katie Dodge Senior Vice President …See details»
Saghmos Therapeutics Announces Notice of Allowance for Second …
Feb 7, 2024 Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI. The company has an issued US patent (Patent number …See details»
Saghmos Therapeutics Welcomes New CRO - Slice of Healthcare
Feb 26, 2024 Stephen Grant, MD, joins Saghmos Therapeutics as Chief Regulatory Officer, bringing over 20 years of FDA experience. Saghmos is developing ST-62516 (trimetazidine), …See details»
HUTCHMED Granted Breakthrough Therapy Designation for
Dec 12, 2024 HUTCHMED has received Breakthrough Therapy Designation from China's National Medical Products Administration for the combination of ORPATHYS® (savolitinib) …See details»
Saghmos Therapeutics Announces Presentation at the Citi Global ...
GREENWICH, Conn., December 03, 2024--Saghmos Therapeutics to participate in a Fireside Chat at the Citi Global Healthcare Conference on Dec. 4th at 8:45 am ET. Live webcast available.See details»
Saghmos Therapeutics | VentureRadar
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is …See details»